Shares of Agenus AGEN moved higher by 0.9% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 9.09% year over year to ($0.20), which beat the estimate of ($0.22).
Revenue of $31,265,000 decreased by 9.38% year over year, which beat the estimate of $16,230,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Agenus hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Mar 15, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/3f7iind8
Price Action
Company's 52-week high was at $5.95
Company's 52-week low was at $1.82
Price action over last quarter: down 9.49%
Company Description
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
